Zobrazeno 1 - 10
of 2 322
pro vyhledávání: '"DPP-4 inhibitors"'
Autor:
Deepanshi Vijh, Promila Gupta
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-16 (2024)
Abstract Diabetes is a metabolic condition defined by abnormal blood sugar levels. Targeting starch-hydrolyzing enzymes and Dipeptidyl Peptidase 4 (DPP-4) expressed on the surface of numerous cells is one of the key strategies to lower the risk of Ty
Externí odkaz:
https://doaj.org/article/ca3de2085ac14ef2a6f2974f3d91739d
Autor:
Mohamed E. A. Mostafa, Tariq Alrasheed
Publikováno v:
Frontiers in Endocrinology, Vol 15 (2024)
BackgroundType 2 diabetes mellitus (T2DM) is linked to a heightened likelihood of experiencing fractures. It is crucial to ascertain whether medications used to lower blood sugar levels can elevate the risk of fractures. We aimed to investigate and c
Externí odkaz:
https://doaj.org/article/47f21d418b0641ccab2fd0fcc4196bbf
Publikováno v:
Frontiers in Cardiovascular Medicine, Vol 11 (2024)
BackgroundThe escalating global economic burden of ischemic stroke poses a significant public health challenge amid global aging trends. The broad therapeutic efficacy of new antidiabetic drugs may offer new options in the prevention and treatment of
Externí odkaz:
https://doaj.org/article/098676a1cb96438992299aa2678a1373
Autor:
Halyna L. Voskoboinikova, Yevhenii P. Bohuslavskyi, Victoria V. Dovzhuk, Liudmyla V. Konovalova, Natela Sh. Dovzhuk
Publikováno v:
Клінічна та профілактична медицина, Iss 3, Pp 13-20 (2024)
The aim of the article. To study of the incidence of diabetes mellitus in Ukraine and to determine the prospects for the use and pharmaceutical development of antidiabetic drugs. Materials and methods. Data from the State Registers of Medicinal Pr
Externí odkaz:
https://doaj.org/article/77253d51262f4dc78dacdaa5709d0e2f
Autor:
Chayah M, Luque-González A, Gómez-Pérez V, Salagre D, Al-Shdaifat A, Campos JM, Conejo-García A, Agil A
Publikováno v:
Drug Design, Development and Therapy, Vol Volume 18, Pp 1133-1141 (2024)
Meriem Chayah,1– 3 Angélica Luque-González,1 Verónica Gómez-Pérez,1 Diego Salagre,4,5 Amjad Al-Shdaifat,6 Joaquín María Campos,1,2 Ana Conejo-García,1,2 Ahmad Agil2,4,5 1Department of Medicinal and Organic Chemistry and Excellence Research
Externí odkaz:
https://doaj.org/article/1754aff403634f7bbf2d2089fe9b3cd1
Autor:
Yoko Narasaki, Csaba P. Kovesdy, Amy S. You, Keiichi Sumida, Yamini Mallisetty, Satya Surbhi, Fridtjof Thomas, Alpesh N. Amin, Elani Streja, Kamyar Kalantar-Zadeh, Connie M. Rhee
Publikováno v:
The Lancet Regional Health. Americas, Vol 36, Iss , Pp 100814- (2024)
Summary: Background: We examined the real-world comparative safety of sodium-glucose cotransporter-2 inhibitors (SGLT2i) vs. other newer anti-glycemic medications (dipeptidyl peptidase-4 inhibitors [DPP4i], glucagon-like peptide-1 receptor agonists [
Externí odkaz:
https://doaj.org/article/578ff3bab1c544c8928fcc8422957606
Publikováno v:
Al-Mustansiriyah Journal of Pharmaceutical Sciences, Vol 24, Iss 3 (2024)
Background: Type 2 diabetes is a complex and diverse disease, and the response to dipeptidyl peptidase-4 inhibitors may exhibit substantial variability between individuals. Several variables may play a role in variances in individual responses to tre
Externí odkaz:
https://doaj.org/article/9991417b8f5e42ad80eba86cf333875b
Publikováno v:
Endocrine and Metabolic Science, Vol 15, Iss , Pp 100174- (2024)
Introduction: It is still controversial about the efficacy of Diptptidyl peptidase-4 (DPP4) inhibitors in the treatment of autoimmune diabetes, especially it is unclear whether different drugs have different efficacy for different subtypes of autoimm
Externí odkaz:
https://doaj.org/article/88f8f80f30c3433aa5b4c42f5d8e4679
Autor:
M. V. Shestakova, G. R. Vagapova, O. K. Vikulova, G. R. Galstyan, T. Yu. Demidova, E. N. Dudinskaya, T. P. Kiseleva, A. M. Mkrtumyan, N. A. Petunina, O. N. Tkacheva, V. V. Fadeev, Y. S. Khalimov, E. A. Shestakova
Publikováno v:
Сахарный диабет, Vol 26, Iss 6, Pp 619-625 (2023)
TThe annual increase in the prevalence of type 2 diabetes mellitus emphasizes the relevance of the search for new treatment options, along with necessity for regular review of proven therapeutic solutions. Today, dipeptidyl peptidase-4 inhibitors (DP
Externí odkaz:
https://doaj.org/article/a9f62b279e3c4b2aa4fd5e55d9c3b6e3
Publikováno v:
Journal of Diabetes, Vol 16, Iss 3, Pp n/a-n/a (2024)
Abstract Objective To assess the association between glucagon‐like peptide‐1 receptor agonists (GLP‐1RA) treatment and the risk of suicide attempts in people with type 2 diabetes (T2D), with a focus on subgroups with and without a history of de
Externí odkaz:
https://doaj.org/article/c46a96f993df4a378e109157fc8b69f9